The European Commission has launched calls for expressions of interest to represent patient, healthcare professional and veterinarian organisations in EMA's Management Board and Pharmacovigilance Risk Assessment Committee (PRAC).

Representatives of civil societies play an important role in the Agency's work, forming members of its scientific committees, reviewing information on medicines produced by the Agency and responding to specific requests for assistance.

For PRAC, one representative of healthcare professional organisations and one alternate will be appointed for a three-year mandate starting on 1 March 2022. The deadline for submission of applications expires on 18 October 2021.

The role of patient and healthcare professional organisation representatives in PRAC is to ensure that the needs and views of the groups they represent, as well as the real-life implications of any committee recommendations, are taken into account during the discussions of the committees.

Two members representing patient organisations, one member representing healthcare professional organisations and one member representing veterinarian organisations will be appointed to the Management Board. The successful candidates will be appointed for a three-year mandate starting on 15 June 2022.

The deadline for submission of applications for the Management Board expires on 5 November 2021.*

The role of the civil society members of the EMA Management Board is to ensure that the views and needs of patients, healthcare professionals and veterinarians are considered in the discussions and decisions taken by the Board.

Further information on the application procedure and the assessment criteria is available on the Commission's website. 


* Deadline extended from 20 October 2021. 

Share this page